Angiotensin II activates nuclear transcription factor-κB through AT1 and AT2 receptors

Kidney International

Volumn 61, Issue 6, 2002, Pages 1986-1995

  Wolf, Gunter ^a,b,c   Wenzel, Ulrich ^a,b,c   Burns, Kevin D ^a,b,c   Harris, Raymond C ^a,b,c   Stahl, Rolf A K ^a,b,c   Thaiss, Friedrich ^a,b,c  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY OF OTTAWA   (Canada)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Angiotensin II; AT2 receptors; Inflammation; Nuclear factor B

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOSARTAN; LUCIFERASE; PROTEIN P50; RANTES; SYNAPTOTAGMIN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL LINE; CELL STRAIN; CELL STRAIN COS7; CONTROLLED STUDY; DNA BINDING; ELECTROPHORESIS; ENDOTHELIUM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; REPORTER GENE;

EID: 0036104265     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00365.x     Document Type: Article

References (54)

1. Vasoactive factors and tubulointerstitial injury
2. Vasoactive hormones and renal sclerosis
3. Angiotensin II-mediated renal injury
4. Molecular mechanisms of angiotensin II in the kidney: Emerging role in the progression of renal disease: Beyond haemodynamics
5. Angiotensin II: A double-edged sword in inflammation
6. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-κB activation and monocyte chemoattractant protein-1 synthesis
7. 1) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy
8. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway
9. NF-κB inhibition ameliorates angiotensin II-induced inflammatory damage in rats
10. 1-receptor antagonists abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis
11. Angiotensin III increases MCP-1 and activates NF-κB and AP-1 in cultured mesangial and mononuclear cells
12. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells
13. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the angiotensin type 2 receptor
14. Nuclear factor-κB - A pivotal transcription factor in chronic inflammatory diseases
15. NF-κB: A key role in inflammatory diseases
16. 2 in vascular smooth muscle cells
17. Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice
18. Distinct contribution of Fc receptors and angiotensin II-dependent pathways in anti-GBM glomerulonephritis
19. 2 receptor stimulation induces generation of ceramides in PC12W cells
20. Angiotensin II is mitogenic for cultured rat glomerular endothelial cells
21. 1 receptor
22. 1 angiotensin II receptor that is present in proximal tubule epithelium
23. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition
24. Involvement of SH2-SH2-SH3 domain of phospholipase Cγl in NF-κB signaling
25. 6 angiotensin II
26. Transcriptional and post-transcriptional alterations of IκBα in active minimal-change nephrotic syndrome
27. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-κB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis
28. 1 receptor inhibition on chemoattractant and adhesion molecule synthesis
29. Effects of early and late antihypertensive treatment on extracellular matrix proteins and mononuclear cells in uninephectomized SHR
30. Renal allograft protection with losartan in Fisher→Lewis rats: Hemodynamics, macrophages, and cytokines
31. ACE inhibitor quinapril reduces the arterial expression of NF-κB-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis
32. Monocyte chemoattractant protein-1 and macrophage infiltration in hypertensive kidney injury
33. Protein traffic activates NF-κB gene signaling and promotes MCP-1-dependent interstitial inflammation
34. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats
35. NF-κB: Ten years after
36. How NF-κB is activated: The role of the IκB kinase (IKK) complex
37. Angiotensin II activates the proinflammatory transcription factor nuclear factor-κB in human monocytes
38. Activation of NF-κB in tubular epithelial cells of rats with intense proteinuria. Role of angiotensin II and endothelin-1
39. Enalapril decreases nuclear factor-κB activation in the kidney with ureteral obstruction
40. 2 receptors
41. From converting enzyme inhibition to angiotensin II receptor blockade: New insight on angiotensin II receptor subtypes in the kidney
42. 2 receptors in the kidney: Role in disease and treatment
43. The angiotensin II type 2 receptor: An enigma with multiple variations
44. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system
45. 1 knockout mice
46. 1 knockout mice
47. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
48. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
49. Renal tubulointerstitial damage caused by persistent proteinuria is attenuated in AT1-deficient mice. Role of endothelin-1
50. Comparison between angiotensin receptor antagonism and converting enzyme inhibition in heart failure
51. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy
52. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study)
53. Comparison of candesartan, enalapril, and their combination in congestive heart failure. Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study
54. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy